KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.

Xun Cao, Jia-Yu Zhou, Hao-Yang Huang, Ling Guo, Ying-Ying Huang, Wen-Ze Qiu, Zhuo-Chen Lin, Ka-Jia Cao, Hao-Yuan Mo, Xian-Ming Li, Zi-Huang Li, Fei Han, Yu-Xiang He, Yu-Meng Liu, Yong-Rui Bai, Shao-Xiong Wu, Liang-Ru Ke, Xi Chen, Chi-Xiong Liang, Zhuo-Ying Luo, Yue Xia, Ying Deng, Jing-Jing Miao, Wei-Xiong Xia, Hu Liang, Chong Zhao, Yan-Qun Xiang, Xiang Guo, Xing Lv

Nat Commun 17(1) 2604

PMID41667463
PMCIDPMC13002903
DOI10.1038/s41467-026-69315-1
发表日期2026-02-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In nasopharyngeal carcinoma, cisplatin is known to be associated with poor treatment compliance and notable side effects. More effective and safer platinum drugs are needed for the treatment of patients with nasopharyngeal carcinoma. In 2021, our multicenter, randomized, phase 3 trial reported that lobaplatin and fluorouracil induction chemotherapy plus concurrent chemoradiotherapy resulted in non-inferior survival and fewer toxic effects than did cisplatin-based therapy in nasopharyngeal carcinoma. Data from the 10-year survival analysis are updated here. With a median follow-up of 10.6 years in the intention-to-treat population, 10-year progression-free survival is 70.7% in the lobaplatin-based therapy group vs. 71.9% in the cisplatin-based therapy group (HR 1.02, 95% CI 0.72-1.43; log-rank p = 0.885). The difference between the groups is 1.2% (95% CI -6.7-9.1, pnon-inferiority = 0.015), which is lower than the prespecified non-inferiority margin of 10%. The results are similar when we analyze patients in the per-protocol population. In the univariable and multivariable analyses, stage is an independent prognostic factor for progression-free survival (p = 0.001). The subgroup analyses suggest that the non-inferiority of lobaplatin-based therapy did not differ among specific populations. The incidence of late toxic effects is similar between the therapy groups, except for grades 1-2 peripheral neuropathy (p = 0.033), grades 1-2 deafness/otitis (p = 0.021), and grades 1-2/3 nephrotoxicity (p = 0.005; p = 0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 2

Fig. 2. Kaplan-Meier survival curves for the lobaplatin-based therapy group and the cisplatin-based therapy group in the intention-to-treat population. A Progression-free Survival, B Overall Survival, C Locoregional Recurrence-free Survival, D Distant Metastasis-free Survival.

A

Progression-free Survival

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Overall Survival

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Locoregional Recurrence-free Survival

Fig. 2 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

Distant Metastasis-free Survival

Fig. 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Trial profile. a One patient without adequate hematological function, two patients without adequate renal function, one patient without adequate hepatic function, and four patients aged >60 years were excluded. b Other drugs included concurrently administered carboplatin and cetuximab. GP gemcitabine and cisplatin.
非 KM Figure
Fig. 3Fig. 3. Subgroup analysis in the intention-to-treat population. A Progression-free Survival, B Overall Survival, C Locoregional Recurrence-free Survival, D Distant Metastasis-free Survival. An unstratified Cox proportional hazards model was used to calculate HRs and 95% CIs, and to execute the interaction test. HR hazard ratio. EBV-DNA Epstein-Barr virus DNA. 1 = Sun Yat-sen University Cancer Center. 2 = Other hospitals.
非 KM Figure